We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Ultrasensitive Sensor Detects Early Stages of Diseases

By LabMedica International staff writers
Posted on 05 Nov 2012
A prototype ultrasensitive sensor has been developed that would enable doctors to detect the early stages of diseases and viruses with the naked eye.

The sensor works by analyzing serum, derived from blood, in a disposable container. More...
If the result is positive for p24, a biomarker that indicates Human Immunosuppressant Virus (HIV) infection, or for Prostate Specific Antigen (PSA), an early indicator for prostate cancer, there is a reaction that generates irregular clumps of nanoparticles, which give off a distinctive blue hue in a solution inside the container. If the results are negative, the nanoparticles separate into ball-like shapes, creating a reddish hue. Both reactions can be easily seen by the naked eye.

The scientific team, from Imperial College London, (United Kingdom) reported that their visual sensor technology is ten times more sensitive than the current gold standard methods for measuring biomarkers. These indicate the onset of various diseases and viral infections. The team said that the sensor can be reconfigured for other viruses and diseases if the specific biomarker is known. The sensor should benefit countries where sophisticated detection equipment is scarce, enabling cheaper and simpler detection, and treatments for patients.

Prof. Molly Stevens, from the departments of materials and bioengineering at Imperial College London, said, “It is vital that patients get periodically tested in order to assess the success of retroviral therapies and check for new cases of infection. Unfortunately, the existing gold standard detection methods can be too expensive to be implemented in parts of the world where resources are scarce. Our approach affords for improved sensitivity, does not require sophisticated instrumentation and it is ten times cheaper, which could allow more tests to be performed for better screening of many diseases.”

The study was reported in the October 2012 journal Nature Nanotechnology.

Related Links:

Imperial College London



New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Urine Analyzer
respons® UDS100
New
Steam Sterilizer
Hi Vac II Line
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.